MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$3,878,807
Free Cash flow
-$1,915,391
Unit: Dollar
Positive Cash Flow Breakdown
Gross proceeds from private plac...
Maturities of marketable securit...
Collaboration receivables
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-2,079,010
-2,417,984
-6,516,521
26,806
Depreciation and amortization
10,741
10,563
10,508
10,552
Impairment of intangible assets
-
-
0
0
Reduction of operating lease right-of-use assets
40,795
31,416
111,230
27,683
Stock-based compensation
109,310
209,510
234,448
254,398
Impairment of in-process r&d
-
-
4,624,000
0
Change in fair value of contingent consideration
89,414
7,427
55,893
-1,721,033
Investment income and fair value adjustments on marketable securities and cash equivalents
61,459
-54,395
-
-41,479
Accretion of discount on marketable securities
8,027
-
112,305
-
Change in accrued interest on marketable securities
78,912
-
164,534
-
Net realized gain on marketable securities
5
-
2,371
-
Change in unrealized gain on cash equivalents
-
-
-119
-
Deferred taxes
-
-
-388,538
-
Loss on disposal of assets
-
-
0
-
Change in unrealized gain on cash equivalents
-14
-
-
-
Prepaid expenses and other current assets
-79,942
221,213
327,734
-306,938
Collaboration receivables
-452,867
21,483
309,544
-1,204,796
Research and development tax credit receivables
0
-
-
-
Tax and other receivables
-91,340
235,647
338,788
1,172,256
Prepaid collaboration expenses
236,111
-176,368
-
-
Other assets
-2,883
27,706
1,555
-2,885
Accounts payable
-378,492
-303,026
655,913
-40,564
Accrued expenses
-44,360
-389,063
233,904
-412,015
Accrued collaboration credit
-
-
-229,251
-189,080
Deferred collaboration revenue
0
-
0
1,250,000
Operating lease liabilities
-40,660
-41,953
-37,095
-27,965
Net cash used in operating activities
-1,891,935
-3,161,332
-2,180,455
-1,273,088
Purchases of property and equipment
23,456
5,018
78,163
431
Purchases of marketable securities
9,122,681
0
0
0
Sales of marketable securities
0
0
0
0
Maturities of marketable securities
2,257,000
5,406,000
5,427,285
5,741,000
Net cash (used in) provided by investing activities
-6,889,137
5,400,982
5,349,122
5,740,569
Gross proceeds from private placement
4,999,848
-
0
0
Issuance costs for private placement
71,701
-
0
0
Taxes paid related to net share settlement of equity awards
9,316
1,012
-
-
Exercise of warrants
0
170
296
0
Proceeds from line of credit
0
-
0
1,750,000
Repayments of line of credit
0
-
0
1,750,000
Net cash provided by financing activities
4,918,831
-842
296
0
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-16,567
20,103
18,755
13,154
Net decrease in cash, cash equivalents and restricted cash
-3,878,807
2,258,910
3,187,718
4,480,635
Cash, cash equivalents and restricted cash, beginning of period
10,960,046
8,701,136
5,513,419
3,796,379
Cash, cash equivalents and restricted cash, end of period
7,081,239
10,960,046
8,701,137
5,513,419
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Gross proceeds from
private placement
$4,999,848
Net cash provided by
financing activities
$4,918,831
(1753.65%↑ Y/Y)
Canceled cashflow
$81,017
Net decrease in
cash, cash...
-$3,878,807
(-40.35%↓ Y/Y)
Canceled cashflow
$4,918,831
Maturities of marketable
securities
$2,257,000
(-79.92%↓ Y/Y)
Collaboration receivables
-$452,867
(-124.93%↓ Y/Y)
Stock-based compensation
$109,310
(-73.43%↓ Y/Y)
Tax and other
receivables
-$91,340
(-413.90%↓ Y/Y)
Change in fair value of
contingent consideration
$89,414
(-78.35%↓ Y/Y)
Prepaid expenses and
other current assets
-$79,942
(81.85%↑ Y/Y)
Change in accrued
interest on marketable...
$78,912
Reduction of operating
lease right-of-use...
$40,795
(-13.87%↓ Y/Y)
Depreciation and
amortization
$10,741
(187.12%↑ Y/Y)
Other assets
-$2,883
(-108.12%↓ Y/Y)
Issuance costs for
private placement
$71,701
Taxes paid related to
net share...
$9,316
Net cash (used in)
provided by investing...
-$6,889,137
(-306.45%↓ Y/Y)
Canceled cashflow
$2,257,000
Net cash used in
operating activities
-$1,891,935
(70.93%↑ Y/Y)
Effect of exchange rate
changes on cash, cash...
-$16,567
(-111.69%↓ Y/Y)
Canceled cashflow
$956,204
Purchases of marketable
securities
$9,122,681
(11.58%↑ Y/Y)
Purchases of property and
equipment
$23,456
(-27.14%↓ Y/Y)
Net loss
-$2,079,010
(52.16%↑ Y/Y)
Accounts payable
-$378,492
(-174.28%↓ Y/Y)
Prepaid collaboration
expenses
$236,111
Investment income and fair
value adjustments on...
$61,459
(78.58%↑ Y/Y)
Accrued expenses
-$44,360
(97.95%↑ Y/Y)
Operating lease
liabilities
-$40,660
(-4.83%↓ Y/Y)
Accretion of discount on
marketable securities
$8,027
Change in unrealized
gain on cash...
-$14
Net realized gain on
marketable securities
$5
Buy us a coffee
KIORA PHARMACEUTICALS INC (KPHMW)
KIORA PHARMACEUTICALS INC (KPHMW)